However, the addition of a TGF‐β1 mAb to renin‐angiotensin inhibitors failed to slow disease progression.[519] Nevertheless, numerous preclinical studies have been conducted in renal fibrosis animal models. This evidence concerns the gene TGFB1 and renal fibrosis.